UiPath Stock Rises As Earnings Beat Fuels AI Growth Story

UiPath Inc. stocks have been trading up by 9.6 percent amid strong investor optimism over accelerating AI automation adoption.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PATH

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For PATH Traders

UiPath delivered Q1 FY27 revenue of about $418M, up 17% year over year and above guidance, while posting its first GAAP operating profit and strong margins and cash flow.
The company grew ARR 11–12% to roughly $1.9B with 109% net retention and $49M in net new ARR, though growth slowed at the low end of the market.
Management raised FY27 revenue guidance to $1.776B–$1.781B and guided Q2 revenue to $395M–$400M, roughly in line with consensus.
PATH shares jumped about 4.5% to $12.10 on the earnings and outlook, even as BofA and Morgan Stanley kept cautious “show‑me” stances with modest target changes.
UiPath continues to lean into its agentic AI automation strategy and was named a Leader in Forrester’s Q2 2026 Wave for document mining, supported by the WorkFusion deal.

Live Update At 12:33:12 EDT: On Monday, June 01, 2026 UiPath Inc. stock [NYSE: PATH] is trending up by 9.6%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PATH has shifted from being a pure growth story to a profitability story, and that matters for trading. UiPath reported Q1 FY27 revenue of roughly $418M, up 17% year over year and ahead of expectations. That kind of double‑digit growth, paired with its first‑ever GAAP operating profit, tells traders the model is finally scaling.

Annual recurring revenue sits around $1.9B, growing 11–12% with a 109% dollar‑based net retention rate. In simple terms, existing customers are spending more, and churn is not the problem. The balance sheet is clean: PATH carries very little debt, with total debt‑to‑equity around 0.03 and a current ratio near 2.5, giving the company plenty of flexibility if macro conditions wobble.

More Breaking News

On valuation, PATH trades at about 3.8x sales and a price‑to‑earnings multiple in the low‑20s, not nosebleed territory for a software name with 80%+ gross margins. The recent move from roughly $9.50 in mid‑May to above $12 shows momentum is back. For short‑term traders, PATH is acting like a name that has found support and is now being re‑rated on better execution.

Why Traders Are Watching PATH Now

The latest quarter changed the tone around PATH. UiPath didn’t just beat on revenue; it proved that its automation platform can throw off real profits. Q1 adjusted EPS of $0.15 missed consensus by a penny, but the Street cared more about the $418.4M revenue print versus the roughly $397.5M estimate and the step into GAAP profitability. When a beaten‑down software stock starts printing cash, traders notice.

That shift feeds straight into the chart. PATH closed at $10.27 on 2026/05/15 and has climbed steadily, finishing at $12.85 on 2026/06/01. The earnings day reaction was clear: shares popped about 4.5% to $12.10 after UiPath raised FY27 revenue guidance to $1.776B–$1.781B, ahead of both prior guidance and consensus. Intra‑day, the 5‑minute tape shows a classic trend‑day grind higher from the $12 area to just under $13, with dips getting bought and tight ranges forming near the highs — a pattern momentum traders love.

Under the hood, PATH’s ARR growth of around 12% and 109% net retention confirm that large customers are sticking with UiPath and expanding use. Management’s outlook for high single‑digit revenue growth and low double‑digit ARR, plus more margin expansion, is anchored on its agentic AI automation strategy and big‑tech partnerships. At the same time, CFRA and others point to slower net new ARR and softness among smaller customers. That’s why BofA, even while lifting its target from $12 to $13, still calls PATH an Underperform, and Morgan Stanley trims its target to $15 with an Equal Weight view. For active traders, that “show‑me” label means this is a catalyst‑driven stock: every ARR update, large deal, or AI product win can move the needle.

Conclusion

For traders who study both numbers and tape, PATH is moving into a new phase. UiPath now combines 80%+ gross margins, positive GAAP operating income, and free cash flow of roughly $179M last quarter with a balance sheet that carries over $871M in cash. That reduces blow‑up risk and gives management room to keep leaning into AI, document mining, and vertical solutions like AML and fraud detection from the WorkFusion acquisition.

The stock’s recent run from the high‑$9s to the mid‑$12s reflects that shift, but Wall Street is not all‑in yet. BofA’s Underperform and Morgan Stanley’s Equal Weight, both with targets in the low‑ to mid‑teens, underscore that PATH still has to prove it can re‑accelerate ARR and convert its agentic AI story into durable large‑deal momentum. That tension between improved fundamentals and lingering skepticism is exactly what short‑term traders look for.

As Tim Sykes often reminds his students, “The market rewards preparation, not prediction — study the pattern, wait for the right setup, and never chase.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.”. Together, those principles highlight that traders don’t need to force trades on PATH; they can wait for clean technical and catalyst‑driven setups. With PATH, that means tracking how price reacts around guidance levels, watching upcoming conferences and ARR commentary, and being ready to cut losses fast if the story breaks. This article is for educational and research purposes only and is not advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!